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Background: The aim of this paper was to examine patterns of 10-year survival after elective repair 
of unruptured abdominal aortic aneurysms (AAA) in different patient groups. 
Methods: Patients having open repair (OR) or endovascular aneurysm repair (EVAR) in the English 
NHS between January 2006 and December 2015 identified from Hospital Episode Statistics data. 
Postoperative survival among patients of different age and Charlson comorbidity profiles were 
analysed using flexible parametric survival models. The relationship between patient characteristics 
and risk of rupture after repair was also analysed. 
Results: 37,138 patients underwent elective AAA repairs, of which 15,523 were open and 21,615 
were endovascular. 10-year mortality was 38% for patients under 70 years, and the survival 
trajectories for OR and EVAR were similar when patients had no RCS comorbidity.  Among older 
patients or those with comorbidity, 10-year mortality rose exceeding 70% for patients aged 80 plus. 
Mean survival times over 10-years for OR and EVAR were often similar within subgroups of older 
and more comorbid patients but their survival trajectories became increasingly dissimilar, with OR 
showing greater short-term risk within 6-months but lower 10-year mortality rates. The risk of rupture 
over 9-years was 3·4% for EVAR and 0·9% for open repair, being weakly associated with patient 
factors. 
Conclusion: Long-term survival patterns after elective OR and EVAR for unruptured AAA vary 
markedly across patients with different age and comorbidity profiles. Judgements about the most 
appropriate technique require shared decision making so patients can balance the short-term and long-
term risks. 
 
Keywords: Abdominal aortic aneurysm, endovascular, long-term survival, flexible parametric 
regression models  








Endovascular repair (EVAR) has become the most common technique for elective repair of 
abdominal aortic aneurysms (AAA) in the UK. In 2007, according to the Hospital Episode Statistics 
database (HES), EVAR procedures accounted for 36% of all first time elective AAA repairs in 
English NHS hospitals, but this had increased to 74% in 2015. Studies on its relative effectiveness 
compared with open repair (OR) have typically found EVAR to have a lower short-term postoperative 
mortality, with a recent systematic review estimating 30-day/in-hospital mortality to be 1·3% 
compared with 4·7% for OR1. However, long-term follow-up of patients in the randomised controlled 
trials (RCT) comparing EVAR with OR have found the early survival benefit of EVAR is not 
sustained2-5. EVARs are susceptible to device failure, endoleaks, migration and other complications 
that require further intervention or surgery and, consequently, there is a need for long term 
surveillance2,4. 
 
The long-term outcomes of elective EVAR and OR have also been examined by various population-
based cohort studies6-9. These benefited from having less restrictive eligibility criteria compared to the 
trials, which in general had patients with fewer comorbidities than the general AAA popualtion10,11, 
but they have produced inconsistent results. Compared with OR, cohort studies have reported EVAR 
to have lower all-cause mortality after 5 years7, or have a higher 4-year mortality rate8,9, while another 
found that survival beyond 3-years was similar for EVAR and OR6. Why these differences have 
arisen is not clear. Possible reasons include the different settings and study time periods as well as 
variation in the degree of heterogeneity within the patient cohorts.  
 
The influence of patient factors such as age and comorbidities (like congestive heart failure, 
respiratory disease and renal impairment) on long-term survival after AAA repair has been well 
documented12 and the large, representative samples of patients in the cohort studies allow for the 




tended to focus on determining the comparative effective of EVAR and OR, using either a standard 
Cox regression8,9 or a method based on propensity scores6,7. Little attention has so far been given to 
how the patterns of short and long-term mortality might differ among patient groups, and in what 
circumstances the hazard ratio of EVAR to OR changes. That the survival curves for EVAR and OR 
cross after several years suggests the hazard ratio may not be constant and the proportional hazards 
assumption required for standard Cox regression is not valid. Schermerhorn et al6 was one exception, 
using piecewise Cox regression to estimate the hazards at 30-days, 90-days, and 4 years post-
intervention, and noted the early advantage of EVAR increased among older patients.  
 
The aim of this study was to examine the long-term risks of death and rupture for unruptured elective 
OR or EVAR in a population-based cohort. These outcomes were investigated for different patient 
groups (defined in relation to patient age and the presence of specified comorbidities) using an 
analytical approach which allowed for the ratio of the mortality rates after EVAR and OR to change 




Patient population and exclusions 
The study used data extracted from the HES database and identified patients admitted for elective 
AAA repair between 1 January 2006 and 31 December 2015. HES records code diagnostic 
information using the International Classification of Diseases, 10th revision (ICD-10), and operative 
procedures using the UK Office for Population Censuses and Surveys classification (OPCS), 4th 
revision. The study cohort contained patients admitted electively with a diagnosis of unruptured AAA 
(ICD-10 code: I71·4) and that had either a first time (index record) OR procedure (L19·4, L19·5, 
L19·6, L19·8) or an EVAR (L27·1, L27·5-9 or L28·1, L28·5-9). The index record was defined as the 
first hospital admission in which a patient had AAA repair. The few index records that described 




procedure as OR but which also contained codes for the use of a stent graft were re-defined as an 
EVAR procedure.  
 
Study variables 
Demographic variables for age and sex were obtained from the index procedure record. The presence 
of comorbidity was described using the Royal College of Surgeons of England’s modified Charlson 
score15. This score is based on 14 acute and chronic conditions that are typically associated with 
survival after surgery, many of which have been linked with worse outcomes in patients who undergo 
AAA repair12 such as: myocardial infarction, congestive heart failure, chronic pulmonary disease, 
renal impairment, cerebrovascular disease, diabetes and peripheral vascular disease. The score counts 
the number of times each chronic condition is recorded in the index admission or is present in HES 
records 12 months prior to this; acute conditions (for example acute myocardial infarction) are only 
counted among records from 12 months prior to the index admission but not the index admission 
itself. The score does not include hypertension or cardiac arrhythmias (atrial fibrillation), and patients 
with a RCS Charlson score of 0 may suffer from some degree of comorbidity. 
 
The primary outcome was postoperative all-cause survival, which was defined as the time from 
surgery to the date of death. The date and cause of death was obtained from the Office for National 
Statistics death register, which provided complete follow-up. However, deaths were rarely attributed 
to abdominal aneurysms beyond the postoperative period and cause of death was therefore 
uninformative about long-term risks and is not reported. The last date of death available was 16 
October 2016, which gave a minimum follow-up time of 290 days. The mean time of follow-up was 
4·4 years. The secondary outcome was time from surgery to any readmission for a ruptured aneurysm 
(defined as ICD-10: I71·1, I71·3, I71·5 & I71·8). 
 
Statistical Analysis  
The pattern of long-term survival among patients having EVAR and open repairs was examined in 




evaluated using Kaplan-Meier survival curves and a standard Cox regression model. Cox regression 
was also used to examine the association of time-to-rupture with these patient characteristics. Log-log 
plots and the Schoenfeld residual test were used to assess whether the survival and time-to-rupture 
data followed the proportional hazards assumption of the Cox regression model16. This assumption 
proved acceptable for time-to-rupture but not for survival. In the latter case, the hazard ratio of EVAR 
compared with OR was found to change over time.  
 
In the second step, the results of the initial Cox model for survival were used to partition the cohort 
into patient groups that distinguished between patient age and presence of comorbidities. The patterns 
of long-term survival within each patient group were analysed using a flexible parametric regression 
model13 with procedure type included as a time-varying variable. This avoided the simplification 
associated with piecewise Cox regression, namely, that the hazards are assumed to be fixed over pre-
defined intervals (the resulting step-functions are rarely plausible biologically13). In flexible 
parametric regression, a restricted cubic spline is used to model the hazard function of each procedure 
as a continuous variable. The appropriate spline was selected using the Akaike Information Criterion 
and Bayesian Information Criterion (measures of how well a statistical model fits the data13) and a 
visual inspection of the hazard functions to avoid overfitting the model. 
 
Because the hazard ratio of EVAR compared with OR was not constant, the differences in estimated 
survival times of the two procedure types are summarised using the restricted mean survival time 
(RMST) 14 for the 10-year follow-up period. This gives the expected survival time for patients having 
either procedure for the specified follow-up period and is a common method for comparing survival 
when the hazards are not proportional. Statistical calculations were performed with Stata version 15·1 








There were 37 138 patients who were admitted for an elective repair of AAA between 1 January 2006 
and 31 December 2015. Only 12·2% of patients were female (Table 1), and the patients who had 
EVAR tended to be older (with a mean age of 75·5 years compared to 71·9 years for OR patients) and 
more inclined to have one or more Charlson comorbidities (68·3% compared to 59·6% for OR). 
 
The 10-year rate of mortality for all patients in the cohort was 59%. There were considerable 
differences between patients of different ages, however. The 10-year mortality was 38% for patients 
aged under 70 years, and this increased to 80% for patients aged 80+ years. The Cox regression model 
confirmed worse survival was associated with increasing age and the presence of any RCS comorbid 
condition (Table 2a), and to a lesser extent with patient sex. The model also suggested the overall 
long-term risk of death was higher among patients having EVAR than patients having open repair 
(adjusted hazard ratio=1·11, 95% confidence interval (CI) 1·07 to 1·16). However, as in previous 
studies8,9, the pattern of survival after EVAR and OR was not consistent with the proportional hazards 
assumption of the standard Cox model, as illustrated in Figure 1 by the crossing of the Kaplan-Meier 
mortality curves around 18 months after surgery. 
 
Rates of AAA rupture after repair 
A total of 397 admissions for ruptured AAA (314 EVAR, 83 OR) were identified during the follow-
up period, with the number rising steadily over time (Figure 2). At 5-years, 1·8% of patients who had 
an EVAR procedure were readmitted with a ruptured diagnosis compared with 0·3% of patients who 
had OR (log-rank test, p<0·001). At 9 years, the rupture rates for EVAR and OR were 3·4 and 0·9%, 
respectively.  
 
The Cox regression model for time from AAA repair to readmission with a ruptured aneurysm is 




(hazard ratio = 3·79, 95% CI 2·95 to 4·87). The risk of rupture was only associated weakly with 
patient age and sex. In addition, although the risk of death on suffering a rupture was around 50% on 
average (Table 3), the low absolute rates of rupture for both procedures means that AAA ruptures 
represented a small proportion of all deaths.  
 
Patterns of long-term survival within patient groups 
To examine how survival after AAA repair was influenced by the patient characteristics, eight groups 
were defined by stratifying patients into four age categories (<70 years, 70-74, 75-79, 80+ years) and 
whether or not a patient had any of the RCS Charlson comorbid conditions. The patterns of 10-year 
mortality for the patient groups are described in Figure 3. The left-hand graphs contain patients who 
did not have any RCS Charlson comorbidity recorded while the right panel includes patients who did. 
The plots show estimated rates of mortality derived from the flexible parametric models (solid lines) 
alongside the Kaplan-Meier estimates (dashed lines) to demonstrate how well the models fit the data. 
  
The graphs in Figure 3 reveal the heterogeneity in the survival trajectories for EVAR and OR across 
the patient groups, over both the short-term postoperative period (up to 12 months) and the 
subsequent 9-years of follow-up. For patients under 70 years with no RCS Charlson comorbidities, 
there was little difference in the mortality curves of the two procedures, and any short-term advantage 
for patients having EVAR was minimal. For both procedures, the expected survival over the 10-year 
follow-up was around 100 months (Table 4). There was also little short-term advantage for EVAR 
among patients under 70 years with a Charlson comorbidity, but the survival trajectories begin to 
diverge after 24 months, such that the expected survival time over the 10 years for OR was 7.3 
months greater than for EVAR (95% CI -9·6 to -5·0; p<0.001). In the other six patient groups, OR 
was associated with a larger short-term risk of death compared with EVAR, with the absolute 
difference increasing among older patients and when patients had a Charlson comorbidity. For 
patients over 80 years with a comorbidity, the absolute difference in short-term survival offered by 





The graphs also show the different durations over which the early survival benefit of EVAR was 
maintained due to the different short-term and longer-term hazards for EVAR and OR. This resulted 
in EVAR having a small but statistically significant advantage over 10 years for patients aged 75-79 
years with no Charlson comorbidity (difference = 3·7, 95% CI 0·7 to 6·7; p<0.001) but the opposite 
was observed for patients aged 75-79 with a comorbidity (difference = -4·5, 95% CI -7·0 to -2.0; 
p<0.001). While patients aged 80+ years with a RCS comorbidity had the largest survival benefit 
from EVAR over the short-term, the longer-term hazard for EVAR was higher than for OR and, at 10-




Information on survival after elective repair of unruptured AAA from randomised clinical trials 
suggest that, while EVAR has higher rates of survival than OR over the first 6 months, this benefit is 
lost over the longer term1-5. The trials have also reported increased rates of rupture among patients 
having EVAR, which has raised concerns about the durability of EVAR. However, the interpretation 
of this evidence has proven contentious and clinical guidelines contain conflicting recommendations 
about which technique is preferred. For example, in the UK, the draft guideline from NICE 
recommended open surgical repair for elective AAA, while the European Society for Vascular 
Surgery Guideline recommended EVAR17,18.  
 
The results from this study extend the evidence base by revealing the variation in the survival 
trajectories after elective EVAR and OR. As expected, increasing age had a strong overall effect, with 
10-year mortality being 38% for patients under 70 years but increasing to 80% for patients over 80. 
But, while previous studies have reported that age and individual comorbidities influence long-term 
survival12, a key finding of this study is how these factors produce different patterns of short-term and 
long-term mortality, which combine to produce an array of survival trajectories for patients having 
EVAR and OR. For patients under 70 years with no RCS comorbidity, the trajectories for EVAR and 




RCS Charlson comorbidity, the absolute difference in short-term survival offered by EVAR compared 
to OR was substantial but after 10 years, the mortality rate for EVAR was higher compared to OR 
(87% vs 79%). The study also found a higher risk of rupture among patients who had EVAR than OR 
(3·4% vs 0·9% after 9 years), which was only weakly associated with patient factors. The low 
absolute rates of rupture for both procedures suggest AAA ruptures contributed only a small 
proportion of all the deaths after AAA repair.  
 
The overall results from this study are consistent with the long-term outcomes reported by the RCTs, 
showing that the early survival advantage of EVAR was lost over a period of 1-3 years1-6. In addition, 
the observed rates of rupture after EVAR and OR are comparable to the results reported by Stather et 
al using pooled data from RCTs and cohort studies (1.9% vs 0.3%, P <0·001)1. Data from the OVER 
trial suggested survival might be better after EVAR among patients younger than 70 years but not 
among those over 705. This finding was not replicated in a meta-analysis of RCT data2, nor by a US 
population-based cohort study6. The latter demonstrated that the early advantage of EVAR was 
greater among patients with increasing age, but the comparative effectiveness of EVAR was only 
reported for the overall cohort and not for any patient subgroups. Desai et al reported gender 
differences in short and long-term survival following OR and EVAR, finding that women had a 
significantly worse long-term survival following OR19. This study also found differences between 
men and women but these were small compared to age and comorbidity. 
 
Evidence on the impact of individual comorbidities on long-term survival after AAA repair was 
summarised in a recent systematic review12, but it did not describe how the survival trajectories might 
be affected, reporting the effects as hazard ratios. In pooled RCT data, Powell et al2 found weak 
evidence to suggest renal dysfunction and coronary artery disease might have a differential effect in 
the first 6 months, whereas peripheral artery disease might have an effect after 6 months. Population-






The economic evaluation undertaken by NICE in developing its draft guideline included age, sex and 
aneurysm diameter in the cost-effectiveness model for elective AAA repair as modifiers of the 
probability of perioperative (30 day) and long-term mortality17. The estimated net benefit of OR 
compared to EVAR reduced as patient age increased, but this was insufficient to change its baseline 
finding that OR was more cost-effective than EVAR.  However, the results might be conservative due 
to the omission of comorbidities and because distinguishing only between peri-operative and long-
term periods of survival will not capture the timeframe over which EVAR and OR show differential 
mortality rates.2,6  The adoption of a consistent set of time points for reporting long-term mortality 
(such as those recommended by the British Society of Endovascular Therapy20) would help these 
limitations be avoided. 
 
This study only stratified patients by two patient characteristics (age and the presence of comorbidity) 
and within each of the groups, there will be heterogeneity among the patients with regard to 
anatomical factors related to their AAA, the combinations of comorbid conditions and their overall 
physical fitness21, all of which will influence short- and long-term outcomes after aortic repair. In 
particular, there may be significant anatomical differences in aneurysm morphology such as a more 
hostile neck anatomy22  which can lead to OR being more appropriate. Among older patients, there 
may be a reluctance to perform OR in the light of the higher perioperative risk, and a willingness to 
compromise on anatomical suitability for EVAR to reduce this risk. 
 
Study strengths and limitations 
Our study has several strengths, in particular, the large number of EVAR and OR procedures. 
Hospital Episode Statistics captures all admissions to English NHS hospitals and therefore the cohort 
is a representative sample. Few elective AAA repairs are performed in independent hospitals. In 
addition, the linkage of patient records to the ONS death register means the study had complete 
follow-up information on all-cause mortality. Finally, the study used data on AAA repairs undertaken 
up until December 2015, which will reflect the use of the more recent EVAR devices as well as the 





The study has several limitations. First, there is the potential for inaccuracies in the coding of AAA 
diagnoses and procedures within HES23, errors which would affect the definition of the patient cohort. 
However, previous studies reported good consistency in the coding of AAA diagnoses and 
procedures24, finding HES to be 94.9% consistent when diagnoses and procedural coding 
combinations were examined. Consequently, bias from misclassifying EVAR and OR procedures is 
unlikely to affect the study results. Bias could arise from the incomplete or miscoding of the comorbid 
conditions included in the RCS Charlson Index15 and data quality might have varied over time. The 
omission of codes is the more common error and would result in patients being wrongly included in 
the “no RCS comorbidity” subgroups.  But any mis-classification bias is unlikely to change the study 
conclusions given the degree of heterogeneity in the long-term survival trajectories observed across 
all the subgroups.  
 
Second, the HES database lacked information on various relevant clinical fields such as the size of the 
aneurysm and other anatomical details of the aorta, which are useful in determining the suitability of a 
patient for either procedure and for risk adjustment. It also lacked information on the EVAR device 
used. There are no data on other known prognostic risk factors including various physiological 
variables (e.g. creatinine) or assessments of fitness like the American Society of Anesthesiologists 
(ASA) grade. This restricted our ability to explore differences between patient groups extensively. 
This could be possible using records from a national, population-based vascular registry if long-term 
follow-up data were available alongside the details of the AAA repair. As the linkage of healthcare 
datasets with other national datasets become more feasible, studies that provide greater insight into the 
survival trajectories for different patients after EVAR and OR will hopefully be forthcoming. 
 
In summary, this study highlights the considerable variation in long-term survival patterns after 
elective OR and EVAR for unruptured AAA across patient groups. This variation arose from changes 
in the short-term and long-term mortality rates associated with patients of different age and other 




implications for clinicians and patients, and the appropriate treatment will depend upon the value 
given to avoiding a poor outcome in the immediate future compared with a potentially longer life 
expectancy25. This has important implications for recommendations in clinical guidelines, suggesting 
a simple recommendation in favour of either OR or EVAR ignores the fact that individuals will face 
different trade-offs when making treatment decisions26. Moreover, these trade-offs will be valued 
differently by patients and surgeons27 and it is important that clinicians can provide patients with 
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AAA, abdominal aortic aneurysm; OR, open repair; EVAR, endovascular repair; RMST, restricted 
mean survival time; RCT, randomised controlled trial; HES, Hospital Episode Statistics; ICD-10, 
International Classification of Diseases, 10th revision; OPCS, UK Office for Population Censuses and 
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Table 1. Patient characteristics at time of procedure among elective AAA repairs performed between 
2006 and 2015, by procedure type. 
 OR % EVAR % Total 
Age group (years)      
  Under 70 5 676 36·6 4 428 20·5 10 104 
  70 to 74 3 889 25·1 4 554 21·1 8 443 
  75 to 79 3 694 23·8 5 933 27·4 9 627 
  80 & over 2 264 14·6 6 700 31·0 8 964 
      
Sex      
  Male 13 388 86·2 19 212 88·9 32 600 
  Female   2 135 13·8   2 403 11·1 4 538 
      
No. of comorbidities (Charlson score)     
  0 6 270 40·4 6 853 31·7 13 123 
  1 5 576 35·9 7 497 34·7 13 073 
  2 or more 3 677 23·7 7 265 33·6 10 942 
      






Table 2a. Results of Cox regression model for survival time of all patients undergoing elective AAA 
repair (n=37 138). 
 Hazard Ratio 95% Confidence interval P value 
Open repair 1   
EVAR 1·11 1·07 to 1·16 <0·001 
    
Age group (years)    
   Under 70 1   
   70 to 74 1·45 1·37 to 1·54 <0·001 
   75 to 79 2·06 1·95 to 2·18 <0·001 
   80 or more 3·11 2·95 to 3·29 <0·001 
    
Male 1   
Female 1·09 1·03 to 1·14 0·001 
    
RCS Charlson Comorbidity Score   
   0 1   
   1 or more 1·72 1·65 to 1·79 <0·001 
 
Table 2b. Results of Cox regression model for time to readmission with a ruptured diagnosis. 
  Hazard Ratio 95% Confidence interval P value 
Open repair 1   
EVAR  3·79 2·95 to 4·87 <0·001 
Age group (years)    
   Under 70 1   
   70-74 0·87 0·62 to 1·20 0·384 
   75-79 1·28 0·96 to 1·70 0·095 
   80 or more 1·43 1·08 to 1·90 0·013 
    
Male 1   
Female 1·37 1·05 to 1·79 0·022 
    
RCS Charlson Comorbidity Score   
  0 1   






Table 3. Readmission and death by ruptured aneurysm. Numbers and percentage of patients 
readmitted with a ruptured diagnosis and percentage experiencing death from ruptured aneurysm 
within 5 years following an initial elective EVAR procedure. 
 
  
Patient group N % ruptured readmission at 5 
years (95% CI) 
% ruptured deaths at 5 years 
(95% CI) 
No RCS Charlson comorbidities   
Under 70 yrs 1 413 1·3 (0·7, 2·3) 0·2 (0·1, 0·7) 
70-74 yrs 1 384 0·9 (0·4, 1·8) 0·4 (0·2, 1·1) 
75-79 yrs 1 801 1·5 (1·0, 2·4) 1·2 (0·7, 1·9) 
80 yrs & over  2 255 2·2 (1·5, 3·1) 1·2 (0·8, 1·8) 
Total 6 853 1·6 (1·2, 2·0) 0·8 (0·6, 1·1) 
One or more RCS Charlson comorbidities  
Under 70 yrs   3 015 1·7 (1·2, 2·4) 0·7 (0·4, 1·1) 
70-74 yrs   3 170 1·7 (1·2, 2·4) 0·7 (0·4, 1·2) 
75-79 yrs   4 132 1·9 (1·4, 2·5) 0·8 (0·6, 1·2) 
80 yrs & over   4 445 2·3 (1·8, 2·9) 1·5 (1·1, 2·0) 




Table 4. Restricted mean survival times (RMST) in months for OR and EVAR procedures over the 
10-year follow-up period, by patient group. 












Difference 95% CI 
No RCS Charlson comorbidities     
Under 70 yrs 105·2 0·7 104·3 1·0 -1·0 -3·4 to 1·5 
70 to 74 yrs 98·6 1·0 99·1 1·1 0·5 -2·4 to 3·4 
75 to 79 yrs 87·8 1·1 91·5 1·1 3·7  0·7 to 6·7 
80 yrs & over 75·3 1·5 73·4 1·0 -1·9 -5·4 to 1·6 
One or more RCS Charlson comorbidities    
Under 70 yrs 96·2 0·8 88·9 0·9 -7·3 -9·6 to -5·0* 
70 to 74 yrs 84·2 0·9 82·1 0·9 -2·1 -4·7 to  0·5 
75 to 79 yrs 75·8 1·0 71·3 0·8 -4·5 -7·0 to -2·0* 




Figure 1. Unadjusted Kaplan-Meier failure estimates for patients undergoing elective OR and EVAR 






Figure 2. Time to rupture cumulative incidence curves for all patients. Outcomes for patients having 







Figure 3. Mortality curves for patients stratified by age. Panels on the left shows patients who did not 
have a comorbidity while panels on the right show patients who did. Outcomes for patients having 
EVAR and ORs are indicated in red and blue, respectively. Dashed and solid lines show curves 








Table S1: Results of Cox regression model for all patients undergoing AAA repair (n = 37,138) 
 
Hazard Ratio 95% Confidence interval P value 
OR 1·00  <0·001 




Age Group (years)   <0·001 
Under 70 1·00   
70 to 74 1·45 1·37 to 1·54  
75 to 79 2·06 1·95 to 2·18  
80 or more 3·11 2·95 to 3·29  
    
Male 1·00  0·001 
Female 1·09 1·03 to 1·14  
    
Charlson Comorbidity Index  
 
0 1·00  <0·001 






Table S2:·Results of the Schoenfeld residual test 
 
 ρ Chi-square 2 Degrees of 
freedom 
Prob> χ2 
EVAR 0·103 134·62 1 <0·001 
Age at procedure   1  
Under 70     
70 to 74 0·011 1·40 1 0·237 
75 to 79 0·026 8·72 1 0·003 
80 or more 0·027 9·47 1 0·002 
Gender 0·008 0·86 1 0·353 
Comorbidity ≥1 -0·070 59·90 1 <0·001 
Global test  221·01 6 <0·001 
 







Figure S1: Log–log plot by procedure. Non-parallel lines indicate non-proportional hazards. 
 
 
 
 
